featured
Lipoprotein(a) Lowering by Alirocumab and Total CV Events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lipoprotein(a) Lowering by Alirocumab Reduces the Total Burden of Cardiovascular Events Independent of Low-Density Lipoprotein Cholesterol Lowering: ODYSSEY OUTCOMES Trial
Eur Heart J 2020 Oct 14;[EPub Ahead of Print], M Szarek, VA Bittner, P Aylward, M Baccara-Dinet, DL Bhatt, R Diaz, Z Fras, SG Goodman, S Halvorsen, RA Harrington, JW Jukema, PM Moriarty, R Pordy, KK Ray, P Sinnaeve, S Tsimikas, R Vogel, HD White, D Zahger, AM Zeiher, PG Steg, GG SchwartzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.